Paricalcitol for secondary hyperparathyroidism in renal transplantation

Matias Trillini, Monica Cortinovis, Piero Ruggenenti, Jorge Reyes Loaeza, Karen Courville, Claudia Ferrer-Siles, Silvia Prandini, Flavio Gaspari, Antonio Cannata, Alessandro Villa, Annalisa Perna, Eliana Gotti, Maria Rosa Caruso, Davide Martinetti, Giuseppe Remuzzi, Norberto Perico

Research output: Contribution to journalArticlepeer-review

Abstract

Secondary hyperparathyroidism contributes to post-transplant CKD mineral and bone disorder. Paricalcitol, a selective vitamin D receptor activator, decreased serum parathyroid hormone levels and proteinuria in patients with secondary hyperparathyroidism. This single-center, prospective, randomized, crossover, open-label study compared the effect of 6-month treatment with paricalcitol (1 μg/d for 3 months and then uptitrated to 2 μg/d if tolerated) or nonparicalcitol therapy on serum parathyroid hormone levels (primary outcome), mineral metabolism, and proteinuria in 43 consenting recipients of renal transplants with secondary hyperparathyroidism. Participants were randomized 1:1 according to a computer-generated sequence. Compared with baseline, median (interquartile range) serum parathyroid hormone levels significantly declined on paricalcitol from 115.6 (94.8-152.0) to 63.3 (52.0-79.7) pg/ml (P

Original languageEnglish
Pages (from-to)1205-1214
Number of pages10
JournalJournal of the American Society of Nephrology
Volume26
Issue number5
DOIs
Publication statusPublished - May 1 2015

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'Paricalcitol for secondary hyperparathyroidism in renal transplantation'. Together they form a unique fingerprint.

Cite this